Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HROW by emailGet an email when HROW pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HROW, unsubscribe in one click. Privacy
📣 What HROW Says Is Next
the end of 2029 · “We expect to launch at least one new product every year between now and the end of 2029 while continuing to invest in expanding the commercial potential of our existing portfolio.”
Company press release, Aug 10, 2026 · SEC filing
fourth quarter of this year · “We continue to expect topline data in the fourth quarter of this year and believe these results have the potential to further highlight NATACYN’s important role in treating fungal keratitis—a serious, sight-threatening infection with significant unmet medical need.”
Company press release, Aug 10, 2026 · SEC filing
in 2027 · “Keep in mind, BYOOVIZ is also only the first of the two ophthalmic biosimilars we acquired from Samsung Bioepis, and we expect to launch OPUVIZ™, our EYLEA-referenced biosimilar, in the United States in 2027, further broadening our comprehensive retina portfolio.”
Company press release, Aug 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HROW picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HROW and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.